Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MYOVANT SCIENCES LTD.

(MYOV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Myovant Sciences : Pfizer Say US FDA Accepted Supplemental New Drug Application for Myfembree, Potential Pain Management Drug

09/09/2021 | 07:51am EST


ę MT Newswires 2021
All news about MYOVANT SCIENCES LTD.
11/23Myovant Sciences to Participate in the Evercore ISI 4th Annual HealthCONx Conference
GL
11/08MYOVANT SCIENCES LTD. : Change in Directors or Principal Officers, Submission of Matters t..
AQ
11/08Myovant Sciences Ltd. Announces Kathleen Sebelius Does Not Stand for Re-Election
CI
11/08Nancy Valente, M.D. Joins Myovant Sciences' Board of Directors
GL
11/08Myovant Sciences Appoints Nancy Valente as Independent Member of its Board of Directors..
CI
10/26Myovant Sciences Reports Fiscal Q2 Results, Pfizer's Non-Exercise Of Exclusive Relugoli..
MT
10/26Myovant Sciences' Fiscal Q2 Loss Narrows
MT
10/26MYOVANT SCIENCES LTD. Management's Discussion and Analysis of Financial Condition and ..
AQ
10/26Myovant Sciences Ltd. Reports Earnings Results for the Second Quarter and Six Months En..
CI
10/26Myovant Sciences Announces Financial Results for Second Quarter of Fiscal Year 2021 and..
PU
More news
Analyst Recommendations on MYOVANT SCIENCES LTD.
More recommendations
Financials (USD)
Sales 2022 242 M - -
Net income 2022 -185 M - -
Net cash 2022 136 M - -
P/E ratio 2022 -9,55x
Yield 2022 -
Capitalization 1 780 M 1 780 M -
EV / Sales 2022 6,80x
EV / Sales 2023 4,49x
Nbr of Employees 407
Free-Float 40,0%
Chart MYOVANT SCIENCES LTD.
Duration : Period :
Myovant Sciences Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MYOVANT SCIENCES LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 19,08 $
Average target price 28,40 $
Spread / Average Target 48,8%
EPS Revisions
Managers and Directors
David C. Marek Chief Executive Officer & Director
Uneek Mehra Chief Financial & Business Officer
Myrtle S. Potter Chairman
Juan Camilo Arjona Ferreira Chief Medical Officer
Jeffrey D. Nornhold Senior VP-Pharmaceutical Operations & Development
Sector and Competitors
1st jan.Capi. (M$)
MYOVANT SCIENCES LTD.-30.92%1 780
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431